Diplomat Pharmacy (NYSE: DPLO) has recently received a number of price target changes and ratings updates:

  • 10/17/2017 – Diplomat Pharmacy was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 10/10/2017 – Diplomat Pharmacy was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $24.00 price target on the stock. According to Zacks, “Diplomat Pharmacy, Inc. operates as an independent specialty pharmacy in the United States. It aids in the dispensing, delivery, dosing and reimbursement of clinically intensive and specialty drugs. The company focuses on medication management programs for people with complex chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, HIV, specialized infusion therapy and many other serious or long-term conditions. Diplomat Pharmacy, Inc. is headquartered in Flint, Michigan. “
  • 10/5/2017 – Diplomat Pharmacy was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 10/4/2017 – Diplomat Pharmacy had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $23.75 price target on the stock, up previously from $19.75.
  • 9/26/2017 – Diplomat Pharmacy was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 9/18/2017 – Diplomat Pharmacy was upgraded by analysts at Robert W. Baird to a “positive” rating. They now have a $24.00 price target on the stock, up previously from $20.00.
  • 9/17/2017 – Diplomat Pharmacy had its “buy” rating reaffirmed by analysts at Robert W. Baird. They now have a $20.00 price target on the stock.
  • 9/15/2017 – Diplomat Pharmacy was upgraded by analysts at BidaskClub from a “sell” rating to a “hold” rating.

Shares of Diplomat Pharmacy, Inc. (NYSE DPLO) opened at 21.14 on Wednesday. The company has a market cap of $1.44 billion, a PE ratio of 115.52 and a beta of 0.73. The firm’s 50-day moving average is $20.24 and its 200-day moving average is $17.38. Diplomat Pharmacy, Inc. has a one year low of $12.25 and a one year high of $26.44.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings results on Monday, August 7th. The company reported $0.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a net margin of 0.27% and a return on equity of 7.97%. The business had revenue of $1.13 billion for the quarter, compared to the consensus estimate of $1.14 billion. During the same period last year, the firm earned $0.23 earnings per share. The company’s quarterly revenue was up 3.5% on a year-over-year basis. On average, equities analysts anticipate that Diplomat Pharmacy, Inc. will post $0.75 EPS for the current year.

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Receive News & Ratings for Diplomat Pharmacy Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc and related companies with MarketBeat.com's FREE daily email newsletter.